Clinical Trials
Vimseltinib shows durable response in tenosynovial giant cell tumor trial
Bhadri et alThe oncologist

Tenosynovial giant cell tumor (TGCT) is a locally aggressive neoplasm driven by colony-stimulating factor 1 (CSF1) gene dysregulation. In the randomized, double-blind, placebo-controlled phase 3 MOTION trial (NCT05059262), investigators evaluated long-term efficacy, safety, and clinical outcome assessments (COAs) for vimseltinib—an oral switch-control tyrosine kinase inhibitor of the CSF1 receptor—in patients with histologically confirmed TGCT not amenable to surgery with more than 2 years of follow-up. The study design incorporated a double-blind phase through week 25 (part 1), an open-label phase from weeks 25 to 49 (part 2), and extension periods, evaluating vimseltinib administered at 30 mg twice weekly.
A total of 118 patients received vimseltinib during MOTION, comprising 83 patients randomized to vimseltinib and 35 crossover patients. Efficacy endpoints included objective response rate (ORR) by independent radiological review per RECIST v1.1 and Tumor Volume Score. At the long-term cutoff, 51% of patients (60/118) remained on study treatment. The RECIST v1.1 ORR was 48% (40/83) in the randomized arm and 54% (19/35) in the crossover arm. Patients in both treatment cohorts experienced long-term improvements in COAs. Safety remained consistent with earlier trial data, with no reported evidence of cholestatic hepatotoxicity or drug-induced liver injury.
Key Takeaways
- With more than 2 years of follow-up, the objective response rate by RECIST v1.1 was 48% (40/83) among patients randomized to vimseltinib and 54% (19/35) in crossover patients, with 51% (60/118) remaining on active therapy.
- The safety profile of vimseltinib remained consistent with prior data, showing no evidence of cholestatic hepatotoxicity or drug-induced liver injury across 118 treated patients.
Read the original sourceThe oncologist
